Form 4: Q32 Bio CFO Kalowski Granted 53,250 RSUs

Q32 Bio Inc.'s CFO and President, Lee Kalowski, was granted 53,250 restricted stock units vesting over three years.

Summary

• Lee Kalowski, CFO and President of Q32 Bio Inc. (QTTB), acquired 53,250 shares of common stock.
• These shares are Restricted Stock Units (RSUs) granted on February 24, 2026.
• The RSUs vest in four equal installments: 25% at 6 months, 12 months, 24 months, and 36 months from the grant date.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• Following this transaction, Kalowski beneficially owns 89,193 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, reflecting the company's commitment to incentivizing its leadership through long-term equity awards, which typically aligns management's interests with shareholder value creation.

Positives

• Grant of 53,250 Restricted Stock Units (RSUs) to CFO and President Lee Kalowski, aligning executive interests with long-term shareholder value.
• The vesting schedule over three years incentivizes long-term commitment and performance from a key executive.

Future Outlook

The vesting schedule for the RSUs extends over three years, indicating a long-term incentive structure for the CFO and President, aligning their future performance with the company's success.

Industry Context

StockSavvy.ai notes that equity grants, particularly Restricted Stock Units (RSUs) with multi-year vesting schedules, are a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key executives. This practice aligns executive interests with long-term shareholder value creation, which is crucial in industries with long development cycles and high R&D costs like biotech.

Comparison to Industry Standards

• The grant of RSUs to a CFO and President is a common executive compensation practice across the biotech sector, comparable to practices at companies like Moderna, BioNTech, or Regeneron, where equity forms a significant portion of executive pay to foster long-term commitment.
• The multi-year vesting schedule (6, 12, 24, 36 months) is typical for executive equity awards, designed to ensure retention and align incentives over strategic planning horizons, similar to vesting schedules seen in grants at companies such as Vertex Pharmaceuticals or Gilead Sciences.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive incentives with long-term company performance and shareholder value.
• Employees: May signal stability in executive leadership and a commitment to long-term growth.

Next Steps

• Future vesting events for the granted RSUs will occur at 6, 12, 24, and 36 months from February 24, 2026.

Key Dates

Recommendation

The grant of Restricted Stock Units to a key executive is a standard practice for executive compensation, aiming to align management's long-term interests with shareholder value. While positive for executive retention and motivation, this single event does not provide sufficient new information to warrant a change in investment recommendation from a seasoned investor's perspective; it reinforces a "hold" position based on existing fundamentals.

Keywords

Q32 Bio Inc., QTTB, Lee Kalowski, CFO, President, Restricted Stock Units, RSUs, Insider Transaction, Executive Compensation, Equity Grant, Form 4